注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Celyad Oncology SA,(原名:Celyad SA)是一家比利時公司。該公司是一家臨床階段的生物技術公司,致力於發現和開髮用於癌症的嵌合抗原受體T細胞(CAR T)療法。該公司為患有血液系統惡性腫瘤和實體瘤的癌症患者開發同種異體和自體CAR T細胞療法候選藥物。該公司的產品CYAD-101是基於細胞活化性(NKG2D)受體的CAR T,它結合了非基因編輯的異基因T細胞抗原受體抑制分子(TIM)技術,用於治療難治性轉移性結直腸癌(mCRC)。它還開發了基於短髮夾核糖核酸(shRNA)的異基因CAR T候選物CYAD-211,用於治療復發或難治性多發性骨髓瘤(r/r MM)。它的自體CAR T專營權正在評估NKG2D受體CAR T候選CYAD-02,用於治療復發或難治性急性髓細胞白血病(r/r AML)和骨髓增生異常綜合症(MDS)。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Michel E. J. Lussier | 68 | 2007 | Co-Founder, Interim CEO & Executive Director |
Marco L. Davila | - | 2016 | Member of Scientific Advisory Board |
Serge Goblet | 66 | 2008 | Non-Executive Director |
Hinrich Abken | - | 2016 | Member of Scientific Advisory Board |
Marina Udier Blagovic | - | 2020 | Independent Director |
Hilde Windels | 59 | 2017 | Independent Chairwoman of the Board |
Dominic G. Piscitelli | 49 | 2020 | Independent Director |
Christopher LiPuma | - | 2022 | Non-Executive Director |
Margo R. Roberts | 69 | 2018 | Member of Scientific Advisory Board |
Gerry Graham | - | - | Member of Scientific Advisory Board |
Ann Ager | - | - | Member of Scientific Advisory Board |
Ami Patel Shah | - | 2021 | Non-Executive Director |
Jean-Christophe Marine | - | - | Member of Scientific Advisory Board |
Andrea Gothing | - | 2024 | Non-Executive Director |
John Campbell | - | - | Member of Scientific Advisory Board |
Jonathan James | - | 2024 | Non-Executive Director |
Sage Mandel | - | 2024 | Non-Executive Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核